# Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

> **NCT04535960** · PHASE2 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 36 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin 25 MG + Liraglutide 1.8 MG
- **DRUG:** Liraglutide 1.8 MG + Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT04535960
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-24
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535960, "Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04535960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*